Longeveron Inc. Granted New Chinese Patent Protecting Potency Assay Methods For Evaluating Human Mesenchymal Stem Cells Through 2041

Longeveron Inc., a clinical-stage biotechnology company developing cell-based therapies for rare pediatric diseases and chronic aging-related conditions, announced that the China National Intellectual Property Administration has granted a new patent covering potency assay methods for evaluating human mesenchymal stem cells (MSCs). 

These MSCs may be derived from bone marrow, adipose tissue, peripheral blood, the lung, heart, amniotic fluid, internal organs, amniotic membrane, umbilical cord, placenta, or produced from induced pluripotent stem cells (iPSCs). Potency assays are a fundamental requirement for demonstrating consistency, quality, and therapeutic activity in approved cell-based products.

The newly granted patent—China Patent No. 2026031300230720, titled “Potency Assay”—provides Longeveron with intellectual property protection in China through 2041, assuming maintenance fees are met. It expands the company’s ability to safeguard the methods used to measure the functional capabilities of its stem cell therapies across a wide range of cell sources.

Dr. Joshua M. Hare, Executive Chairman and Chief Science Officer of Longeveron, noted that this patent strengthens the company’s international patent estate, which now includes 52 patents worldwide. He emphasized that a robust global intellectual property portfolio is a strategic advantage as Longeveron advances its mission to develop stem cell therapies that may benefit patients and families affected by complex and life-threatening conditions.

Longeveron has previously evaluated its lead investigational product, laromestrocel (Lomecel-B), in clinical studies for Alzheimer’s disease (Phase 1 and 2), Aging-related Frailty (Phase 1 and 2), and Hypoplastic Left Heart Syndrome (HLHS) (Phase 1), a rare pediatric disorder that carries orphan disease designation. The company is currently conducting a potentially pivotal Phase 2b clinical trial of laromestrocel in HLHS, with results expected in the third quarter of 2026. Depending on the outcome of this study, the data may support a future Biologics License Application submission to the U.S. FDA for this indication.

The newly granted Chinese patent further strengthens Longeveron’s global protection for its therapeutic platform as the company progresses toward key clinical milestones and long-term commercialization pathways.